News Bulletins

Healthful Newsletters from Carlson Laboratories

Carlson Fish Oils - Part of a Major Research Study

A study is in progress investigating the effect of intervention factors on patients with type 2 diabetes mellitus and coronary artery disease (CAD).

CAD is the major complication of both type 1 and type 2 diabetes mellitus. Diabetes is increasing at an epidemic rate with 151 million cases in 2000 forecasted to double by 2025. Guidelines are needed to address this problem. The new study is aimed at evaluating various intervention factors.

Factors being investigated as part of a possible treatment program are:

The use of weight management Lowering cholesterol, blood pressure, and triglycerides Smoking cessation Diet and exercise Drugs Fish oils and others

A total of 2,368 patients have been enrolled at 49 clinical centers in North America, South America, and Europe. The study started in 2005 and is expected to extend to at least May 2007.

Carlson Laboratories is supplying the fish oil needed in the study. Other firms such as Abbott Laboratories, Bayer Diagnostics, Eli Lilly, Merck & Co., and Pfizer Inc. are supplying drugs and equipment for this study.

Disclaimer: The statements and information upon this website have not necessarily been evaluated by the Food and Drug Administration. The products featured are not intended to diagnose, treat, cure or prevent any disease. Consumers should always consult their own medical practitioner(s) with any medical or health concerns before starting any new diet, product or supplement.